Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin in Neonatal Encephalopathy
NCT04432662Phase 2Recruiting
- Sponsor
- Imperial College London
- Start
- May 2021
- Primary completion
- Sep 2024
- Modality
- Erythropoietins, Colony Stimulating Factors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in neonatal encephalopathy (NE) comparing Darbepoetin Alpha with Standard of care (2 arms). Primary endpoint: Mean (SD) of thalamic N-acetylaspartate level. Started May 2021; status: recruiting.
02
Drugs
darbepoetin alfa
03
Conditions
neonatal encephalopathy (NE)
Beyond the preview
Go deeper on NCT04432662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04432662.